Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Zhaoke Ophthalmology Ltd. ( (HK:6622) ) is now available.
Zhaoke Ophthalmology Limited announced its unaudited consolidated interim results for the six months ended June 30, 2025, revealing a significant decrease in revenue from RMB 49,769,000 in 2024 to RMB 15,803,000 in 2025. Despite a reduction in selling and distribution expenses, the company reported a loss of RMB 116,623,000 for the period, largely due to increased R&D expenses, which reflects its continued investment in product development. The announcement highlights the financial challenges the company faces, impacting its market position and stakeholder confidence.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company incorporated in the British Virgin Islands and continued in the Cayman Islands, focusing on the ophthalmology industry. The company is involved in the development and commercialization of ophthalmic products, catering to the needs of patients with eye-related conditions.
Average Trading Volume: 3,351,101
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.12B
Find detailed analytics on 6622 stock on TipRanks’ Stock Analysis page.